DZ Bank Call 4.748 MDG2 20.12.202.../ DE000DW83PA7 /
| 9/26/2024 12:04:42 PM | Chg.0.000 | Bid9/26/2024 | Ask- | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 0.001EUR | 0.00% | - Bid Size: - |
- Ask Size: - |
MEDIGENE AG NA O.N. | 4.748 EUR | 12/20/2024 | Call |
GlobeNewswire
8/29
Medigene AG Secures Two Additional Patents for Technologies in Its End-to-End Platform
GlobeNewswire
8/26
Medigene AG implements announced 2:1 share capital reduction and consolidation of the shares effecti...
GlobeNewswire
8/14
Medigene AG Reports Half-Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire
8/8
Medigene and WuXi Biologics Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell ...
GlobeNewswire
7/3
Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell ...
GlobeNewswire
6/27
Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness
GlobeNewswire
6/20
Medigene AG Announces Lead Selection for MDG2021, Expanding TCR-T KRAS Library Targeting Solid Tumor...
GlobeNewswire
5/28
Medigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology ...
GlobeNewswire
5/21
Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announ...
GlobeNewswire
5/15
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
GlobeNewswire
5/14
Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise
GlobeNewswire
5/6
The Benchmark Company Announces Upcoming Healthcare House Call VIRTUAL One-on-One Investor Conferenc...
GlobeNewswire
5/2
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell R...
GlobeNewswire
5/2
Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch Protein
